0K30 Stock Overview
A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TFF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.62 |
| 52 Week High | US$8.00 |
| 52 Week Low | US$1.62 |
| Beta | 1.38 |
| 11 Month Change | -16.92% |
| 3 Month Change | -73.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.5% | -5.6% | -0.1% |
| 1Y | n/a | -18.5% | 2.3% |
Return vs Industry: Insufficient data to determine how 0K30 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0K30 performed against the German Market.
Price Volatility
| 0K30 volatility | |
|---|---|
| 0K30 Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0K30's share price has been volatile over the past 3 months.
Volatility Over Time: 0K30's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 19 | Harlan Weisman | tffpharma.com |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
TFF Pharmaceuticals, Inc. Fundamentals Summary
| 0K30 fundamental statistics | |
|---|---|
| Market cap | €4.80m |
| Earnings (TTM) | -€18.58m |
| Revenue (TTM) | €825.84k |
5.8x
P/S Ratio-0.3x
P/E RatioIs 0K30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K30 income statement (TTM) | |
|---|---|
| Revenue | US$885.72k |
| Cost of Revenue | US$11.50m |
| Gross Profit | -US$10.62m |
| Other Expenses | US$9.31m |
| Earnings | -US$19.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.43 |
| Gross Margin | -1,198.52% |
| Net Profit Margin | -2,249.82% |
| Debt/Equity Ratio | 0% |
How did 0K30 perform over the long term?
See historical performance and comparison